Is Pembrolizumab pd1 or pdl1?

Pembrolizumab is a PD-1 (programmed death-1) inhibitor, not a PD-L1 (programmed death ligand-1) inhibitor. PD-1 and PD-L1 are two proteins on the surface of immune cells, and their interaction can inhibit the immune system's ability to attack cancer cells. Pembrolizumab, as an inhibitor of PD-1, blocks the binding of PD-1 to its ligand PD-L1, thereby removing the inhibition of cancer cells from attacking immune cells, thereby enhancing the body's immune system's ability to attack cancer cells.

The PD-1 ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T cells and inhibit T cell proliferation and cytokine production. Upregulation of PD-1 ligand occurs in some tumors, and signaling through this pathway may contribute to suppression of active T cell immune surveillance of tumors. Although pembrolizumab is an inhibitor against PD-1, in clinical applications, doctors usually evaluate the expression level of PD-L1 in tumor tissues to assist treatment decisions. Therefore, in individualized treatment plans, considering the expression of PD-L1 is also one of the important factors.

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.